论文部分内容阅读
探讨蚓激酶胶囊对非胰岛素依赖型糖尿病合并周围神经病变 (DPN)的抗凝溶栓作用。方法 :将DPN分常规治疗和蚓激酶治疗 ,分别测定 2组治疗前后空腹血糖 (FBG) ,血小板α颗粒膜蛋白 14 0 (GMP -14 0 ) ,血栓素 β2 (TXβ2 ) ,血小板聚集率及血浆纤维蛋白原浓度 (Fg) ,与正常对照组比较。结果 :DPN者GMP -14 0 ,TXB2 血小板聚集率均明显高于对照组 (P <0 .0 1) ,蚓激酶治疗后 ,GMP -14 0 ,TXB2 ,血小板聚集率Fg含量较疗前明显下降 (P<0 .0 1)与常规对照组比较亦有显著差异 (P<0 .0 1)。结论 :蚓激酶胶囊对DNP有溶栓及抑制血小板聚集作用。
To investigate the anticoagulant thrombolytic effect of lumbrokinase capsule on non-insulin-dependent diabetic patients with peripheral neuropathy (DPN). Methods: DPN was divided into routine treatment and lumbrokinase treatment. The levels of fasting blood glucose (FBG), platelet α-membrane protein 140 (GMP-140), TXβ2, platelet aggregation and plasma Fibrinogen concentration (Fg), compared with the normal control group. Results: The platelet aggregation rate of GMP -140 and TXB2 in DPN group was significantly higher than that in control group (P <0.01). After treatment with lumbrokinase, the levels of GMP -140, TXB2 and platelet aggregation rate were significantly decreased (P <0. 01) compared with the conventional control group also had significant differences (P <0.01). Conclusion: Lumbrokinase capsules have the effect of thrombolysis and inhibition of platelet aggregation in DNP.